WASHINGTON, D.C.—Timothy Cost, a 30-year corporate-affairs and investor-relations veteran with executive experience at several of the world’s top health-care companies, has been named global chair, healthcare, and executive vice president at APCO Worldwide. Cost served most recently as senior vice president, corporate affairs, for Wyeth, the $22-billion global health-care company recently acquired by Pfizer.
“The landscape has changed, and companies need to be better aligned, faster and more integrated in their marketing, policy and communication than ever before,” says Cost. “APCO is well positioned to help senior leadership execute on this challenge.”
Cost joins a diverse team of health experts at APCO, including Courtney Piron, head of the firm’s health policy practice and former director in Pfizer’s economic and policy research group; Wayne Pines, former associate commissioner for public affairs at the U.S. Food and Drug Administration; Ken Thorpe, former deputy assistant secretary at the U.S. Department of Health and Human Services; Kirsten Thistle, head of the Washington, D.C., health practice and expert on science and risk communication; Bill Pierce, former deputy assistant secretary for public affairs at HHS; and Tresja Bolt, who leads APCO’s health-care work in the Europe, Middle East and Africa region.
While at Wyeth, Cost had global responsibility for the company’s internal and external communication efforts, government affairs, public policy, alliance and advocacy leadership, corporate contributions, crisis management, investor relations and corporate responsibility.
Prior to joining Wyeth, he was executive vice president, corporate affairs, at management-services giant Aramark. Earlier in his career, he served as senior vice president, corporate affairs, at Pharmacia Corporation, a global pharmaceutical company that was acquired by Pfizer in 2003. He also spent six years at Bristol-Myers Squibb, leading the company’s investor relations and competitive intelligence activities, and was senior vice president, communications and strategy, for biotechnology company Centocor (now part of Johnson & Johnson).